Evidence map›Paper›PMID 33128684›Full record

ArticleMolecular biology reports2020

Uncovering the expression patterns and the clinical significance of miR-182, miR-205, miR-27a and miR-369 in patients with urinary bladder cancer.

Nouha Setti Boubaker, Aymone Gurtner, Nesrine Trabelsi, Isabella Manni, Haroun Ayed, Ahmed Saadi, Zeineb Naimi, Meriem Ksontini, Mouna Ayadi, Ahlem Blel and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Nouha Setti BoubakerLaboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia. nouha.setti@hotmail.fr.ORCID http://orcid.org/0000-0001-8342-6936
Aymone GurtnerUOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.ORCID https://orcid.org/0000-0002-7661-9059
Nesrine TrabelsiLaboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia.
Isabella ManniUOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Haroun AyedLaboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia.
Ahmed SaadiLaboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia.ORCID https://orcid.org/0000-0002-5361-9005
Zeineb NaimiMedical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia.ORCID https://orcid.org/0000-0002-9511-5403
Meriem KsontiniPathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia.
Mouna AyadiMedical Oncology Department, Salah Azaiez Institute, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia.
Ahlem BlelPathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia.ORCID https://orcid.org/0000-0001-6702-3889
Soumaya RammehPathology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia.ORCID https://orcid.org/0000-0003-0366-4630
Mohamed ChebilUrology Department, Charles Nicolle Hospital, Faculty of Medicine, University of Tunis-El Manar, Tunis, Tunisia.ORCID https://orcid.org/0000-0001-8387-7593
Giulia PiaggioUOSD SAFU, Department of Research, Diagnosis and Innovative Technologies, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. giulia.piaggio@ifo.gov.it.ORCID https://orcid.org/0000-0003-2114-1892
Slah OuerhaniLaboratory of proteins engineering and bioactive molecules (LIP-MB), INSAT, University of Tunis Carthage, Tunis, Tunisia.ORCID https://orcid.org/0000-0002-3651-4690
Tunis El Manar University · TNNational Institute of Applied Science and Technology · TNIstituto di Farmacologia Traslazionale · ITNational Cancer Institute · MYUniversity of Carthage · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven the high recurrence and progression rates and the absence of reliable markers for early detection and prognosis prediction of patients with urothelial bladder cancer (BCa), the exploration of new biomarkers with high specificity is imperative. Mainly, microRNAs (miRNAs), which are involved in the initiation and the progression of BCa. Herein, the expression patterns of miR-182, miR-205, miR-27a and miR-369 were evaluated in patients with urothelial BCa. METHODS AND

resultsThe expression levels of the miRNAs were investigated in 90 FFPE tissue samples (23 LG NMIBC, 44 HG NMIBC, 23 MIBC) and 10 non tumoral bladder tissues using TaqMan based RT-qPCR. Data analysis was performed using 2

conclusionCollectively, a selection of miRNAs was found to be aberrantly expressed in BCa suggesting a potential diagnostic value in BCa. In addition, the clinical value of miR-182 and miR-205 as potential prognosis biomarkers was highlighted. Indeed, our data provide additional insights into cancer biology. Further functional or target studies are mandatory to strengthen these findings.

Indexed as

Gene Expression Regulation, NeoplasticAgedAged, 80 and overFemaleGene Expression ProfilingHumansMaleMicroRNAsMiddle AgedNeoplasm Recurrence, LocalPrognosisROC CurveUrinary Bladder NeoplasmsMicroRNAsMIR205, humanMirn182 microRNA, humanMIRN27 microRNA, humanMIRN369 microRNA, humanBladder cancerDiagnosisEpigeneticExpression profilesMicroRNAPrognosis

Identifiers

PMID33128684
OpenAlexW3097459404

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.